Evaluation of collagenase Clostridium histolyticum for the treatment of Peyronie’s disease

Bibliography

• Nelson CJ, Diblasio C, Kendirci M, et al. The chronology of depression and distress in men with Peyronie’s disease. J Sex Med 2008;5(8):1985-90
   PubMed Web of Science ®Google Scholar
• Rosen R, Catania J, Lue T, et al. Impact of Peyronie’s disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med 2008;5(8):1977-84
   PubMed Web of Science ®Google Scholar
• Smith J F, Walsh TJ, Conti SL, et al. Risk factors for emotional and relationship problems in Peyronie’s disease. J Sex Med 2008 5(9):2179-84
   Google Scholar
• Taylor FL, Abern MR, Levine LA. Predicting erectile dysfunction following surgical correction of Peyronie’s disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factors. J Sex Med 2012;9(1):296-301
   PubMed Web of Science ®Google Scholar
• Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s Disease: AUA Guideline. J Urol 2015;194(3):745-53
   PubMed Web of Science ®Google Scholar
• Dibenedetti DB, Nguyen D, Zografos L, et al. A population-based study of peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol 2011;2011:282503
   PubMedGoogle Scholar
• Taylor FL, Levine LA. Peyronie’s Disease. Urol Clin North Am 2007;34(4):517-34, vi
   PubMed Web of Science ®Google Scholar
• Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997;158(4):1388-90
   PubMed Web of Science ®Google Scholar
• Somers KD, Sismour EN, Wright GL, et al. Isolation and characterization of collagen in Peyronie’s disease. J Urol 1989;141(3):629-31
   PubMed Web of Science ®Google Scholar
• Mulhall JP. Expanding the paradigm for plaque development in Peyronie’s disease. Int J Impot Res 2003;15(Suppl 5):S93-102
   PubMed Web of Science ®Google Scholar
• Chiang PH, Chiang CP, Shen MR, et al. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie’s disease. Eur Urol 1992;21(1):48-51
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Yassin AA. Conservative treatment for Peyronie’s disease: an update. Expert Opin Pharmacother 2008;9(1):53-63
   PubMed Web of Science ®Google Scholar
• Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of peyronie’s disease. Br J Urol 1982;54(6):748-50
   PubMedGoogle Scholar
• Ralph DJ, Schwartz G, Moore W, et al. The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997;157(1):291-4
   PubMed Web of Science ®Google Scholar
• Nyberg LMJ, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982;128(1):48-51
   PubMed Web of Science ®Google Scholar
• Nachtsheim DA, Rearden A. Peyronie’s disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996;156(4):1330-4
   PubMed Web of Science ®Google Scholar
• Schiavino D, Sasso F, Nucera E, et al. Immunologic findings in Peyronie’s disease: a controlled study. Urology 1997;50(5):764-8
   PubMed Web of Science ®Google Scholar
• Rompel R, Mueller-Eckhardt G, Schroeder-Printzen I, Weidner W. HLA antigens in Peyronie’s disease. Urol Int 1994;52(1):34-7
   PubMed Web of Science ®Google Scholar
• Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomena in etiopathogenesis? Tissue Antigens 1991;38(3):104-6
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol 2006;175:2115-18; discussion 2118
   PubMed Web of Science ®Google Scholar
• Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med 2010;7(7):2359-74
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Dorey F, James K. The natural history of Peyronie’s disease. J Urol 1990;144(6):1376-9
   PubMed Web of Science ®Google Scholar
• Auxilium Pharmaceuticals. Pharmacokinetics of a single treatment cycle of AA4500 0.58 mg in men with Peyronie’s Disease. Bethesda, MD: National Library of Medicine (US), 2011. clinicaltrials.gov
   Google Scholar
• Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 2007;17:972-5
   Web of Science ®Google Scholar
• Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol 2012;62(3):543-52
   PubMed Web of Science ®Google Scholar
• Trost LW, Ates E, Powers M, et al. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol 2013;190(6):2194-9
   PubMed Web of Science ®Google Scholar
• Levine LA, Dimitrou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie’s disease. Int J Impot Res 2000;12(3):147-51
   PubMed Web of Science ®Google Scholar
• Taylor FL, Abern MR, Levine LA. Predicting erectile dysfunction following surgical correction of Peyronie’s disease without inflatable penile prosthesis placement: Vascular assessment and preoperative risk factors. J Sex Med 2012;9(1):296-301
   PubMed Web of Science ®Google Scholar
• Levine LA, Lenting E. A surgical algorithm for the treatment of Peyronie’s disease. J Urol 1997;158:2149-52
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: Functional and satisfaction outcomes. J Sex Med 2005;2:132-8
   PubMed Web of Science ®Google Scholar
• Levine LA, Benson J, Hoover C. Inflatable penile prosthesis placement in men with Peyronie’s disease and drug-resistant erectile dysfunction: a single-center study. J Sex Med 2010;7:3775-83
   PubMed Web of Science ®Google Scholar
• Levine LA, Burnett AL. Standard operating procedures for Peyronie’s disease. J Sex Med 2013;10(1):230-44
   PubMed Web of Science ®Google Scholar
• Yafi FA, Sangkum P, McCaslin IR, Hellstrom WJ. Strategies for penile prosthesis placement in Peyronie’s disease and corporal fibrosis. Curr Urol Rep 2015;16(4):21
   PubMedGoogle Scholar
• Harris EDJ, Krane SM. Collagenases (first of three parts). N Engl J Med 1974;291(11):557-63
   PubMed Web of Science ®Google Scholar
• Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009;361(10):968-79
   PubMed Web of Science ®Google Scholar
• Friedman K, Pollack S V, Manning T, Pinnell SR. Degradation of porcine dermal connective tissue by collagenase and hyaluronidase. Br J Dermatol 1986;115(4):403-8
   PubMed Web of Science ®Google Scholar
• Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 2007;32(6):767-74
   PubMed Web of Science ®Google Scholar
• Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren’s disease. J Hand Surg Am 2000;25(4):629-36
   PubMed Web of Science ®Google Scholar
• Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJG. Therapeutic advances in the treatment of Peyronie’s disease. Andrology 2015
   Google Scholar
• Mandl I, Maclennan JD, Howes EL. Isolation and characterization of proteinase and collagenase from Cl. histolyticum. J Clin Invest 1953;32(12):1323-9
   PubMed Web of Science ®Google Scholar
• Mandl I, Zipper H, Ferguson LT. Clostridium histolyticum collagenase: Its purification and properties. Arch Biochem Biophys 1958;74(2):465-75
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res 1982;10(3):135-40
   PubMed Web of Science ®Google Scholar
• French MF, Mookhtiar KA, Van Wart HE. Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry 1987;26(3):681-7
   PubMed Web of Science ®Google Scholar
• Luangkhot R, Rutchik S, Agarwal V, et al. Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J Urol 1992;148(2 Pt 1):467-71
   PubMed Web of Science ®Google Scholar
• Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med 2008;5(9):2221-8
   PubMed Web of Science ®Google Scholar
• Levine L.A, Cuzin B, Mark S, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie’s disease: a phase 3 open-label study. J Sex Med 2015;12(1):248-58
   PubMed Web of Science ®Google Scholar
• Bergsma J, Boelen MK, Duursma AM, et al. Complexes of rat alpha 1-macroglobulin and subtilisin are endocytosed by parenchymal liver cells. Biochem J 1985;226(1):75-84
   PubMed Web of Science ®Google Scholar
• Sottrup-Jensen L, Birkedal-Hansen H. Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 1989;264(1):393-401
   PubMed Web of Science ®Google Scholar
• Feinman RD. The proteinase-binding reaction of alpha 2M. Ann N Y Acad Sci 1994;737:245-66
   PubMed Web of Science ®Google Scholar
• Gliemann J, Nykjaer A, Petersen CM, et al. The multiligand alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP). Binding and endocytosis of fluid phase and membrane-associated ligands. Ann N Y Acad Sci 1994;737:20-38
   PubMed Web of Science ®Google Scholar
• Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol 1985;134(2):280-3
   PubMed Web of Science ®Google Scholar
• Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993;149(1):56-8
   PubMed Web of Science ®Google Scholar
• Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190(1):199-207
   PubMed Web of Science ®Google Scholar
• Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 2012;187:2268-74
   PubMed Web of Science ®Google Scholar
• Risk evaluation and mitigation strategy of xiaflex for treating peyronie’s disease. Available from: www.xiaflexrems.com/peyronie.php [Last accessed 8th September 2015]
   Google Scholar